📰 Confidence Interval News
Page 21 - Confidence Interval News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Confidence Interval. Real-time updates on events, politics, business and more.
September 5, 2023
The clinical trial compared outcomes in patients with NAFLD on a resistant starch diet to a control group over a 4-month period, with results suggesting microbiota dietary supplements may improve liver conditions.
September 1, 2023
Results from the study found a high risk of CDI associated with clindamycin and low risk associated with doxycycline and minocycline, also highlighting variation in CDI risk within and between classes of antibiotics.
August 31, 2023
Carolina Mangas-Sanjuan, MD, PhD, discusses findings from her research on the use of artificial intelligence computer-aided detection in colonoscopies in this Q&A with HCPLive.
August 29, 2023
Results from two recent studies highlight the potential benefits and limitations of using artificial intelligence technologies in colonoscopies.
August 28, 2023
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
August 25, 2023
25.08.2023 - The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis ...
August 23, 2023
/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...
August 22, 2023
An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.
August 12, 2023
India News: A survey has said Prime Minister Narendra Modi is far ahead of Congress leader Rahul Gandhi as far as engagements and viewerships on social media plat
August 11, 2023
1. In this randomized controlled trial, dupilumab use was associated with significantly fewer chronic obstructive pulmonary disease (COPD) exacerbations among patients with type two inflammation as compared to a placebo. 2. The incidence of adverse events leading to treatment discontinuation or death and serious adverse events was not significantly different between groups. Evidence Rating Level: